Sees FY25 Adjusted EBITDA $310M-$340M. Sees FY25 R&D Expenses $305M-$335M; and SG&A Expenses $655M-$685M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on ALKS: Alkermes reports Q4 non-GAAP EPS $1.05, consensus 76c Alkermes initiated with a Buy at Deutsche Bank ALKS Earnings Report this Week: Is It a Buy, Ahead of Earnings? Alkermes price target raised to $33 from $31 at BofA Alkermes Advances Orexin Program with ALKS 2680 Candidate Disclaimer & DisclosureReport an Issue
